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Abstract: Background: RNA editing is a highly conserved posttranscriptional mechanism that
contributes to transcriptome diversity. In mammals, it includes nucleobase deaminations that
convert cytidine (C) into uridine (U) and adenosine (A) into inosine (I). Evidence from cancer studies
indicates that RNA-editing enzymes promote certain mechanisms of tumorigenesis. On the other
hand, recoding editing in mRNA can generate mutations in proteins that can participate in the Major
Histocompatibility Complex (MHC) ligandome and can therefore be recognized by the adaptive
immune system. Anti-cancer treatment based on the administration of immune checkpoint inhibitors
enhance these natural anti-cancer immune responses. Results: Based on RNA-Seq datasets, we
evaluated the editome of melanoma cell lines generated from patients pre- and post-immunotherapy
with immune checkpoint inhibitors. Our results reveal a differential editing in Arthrobacter luteus
(Alu) sequences between samples pre-therapy and relapses during therapy with immune checkpoint
inhibitors. Conclusion: These data pave the way towards the development of new diagnostics and
therapies targeted to editing that could help in preventing relapses during immunotherapies.
Keywords: editing; melanoma; ADAR; Alu sequences; immune checkpoint inhibitors; immunotherapy
1. Introduction
The diversification of messenger RNA (mRNA) sequences from genomic DNA relies
on posttranscriptional mechanisms, such as alternative splicing and RNA editing [1,2].
In mammals, RNA editing involves the deamination of adenosines (A) or cytidines (C)
generating in situ inosine (I) or uridine (U), respectively. While adenosine deaminase acting
on RNA (ADAR) [3] and adenosine deaminase acting on tRNA (ADAT) [4] deaminate A
residues, enzymes from the APOBEC family [5] deaminate C residues. In the following, we
focus on ADAR activities, as A-to-I modifications globally represent 97% of RNA editing
events [6], in mammals and especially in humans. A-to-I editing events can occur in coding
and non-coding sequences of mRNA [7]. In general, they are prominent in double-stranded
RNA stretches formed by inverted non-coding repeats such as Arthrobacter luteus (Alu)
and long interspersed element (LINE) located in mRNA untranslated regions (UTRs) and
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introns [8–10]. RNA editing in non-coding sequences can influence alternative splicing,
nuclear retention, and transcript degradation (e.g., recognition by miRNA) [11]. In addition,
RNA editing can affect sites in the protein coding region of mRNAs, leading to potential
amino acid changes, known as recoding editing [12]. In humans, recoding editing is rare
while A-to-I in Alu elements is abundant and accounts for 97% of all available events [13].
Both ADAR1 and ADAR2 can perform recoding or non-recoding editing. A third ADAR
protein called ADAR3 is expressed only in the brain and its deaminase activity has not
been yet proven [7].
A-to-I RNA editing is essential in maintaining cellular homeostasis [14–16] and has
been implicated in several diseases ([17] reviewed in [18–20]). In particular, the disruption
of the controlled expression of ADAR1 and ADAR2 has been shown to contribute to cancer
pathogenesis. Based on current reports, recoding and non-coding editomes with hypo-
or hyper-editing levels appear to be dependent on cancer-types and genes [21,22]. For
example, the DNA base excision repair glycosylase enzyme NEI-like protein 1 (NEIL1),
encoding antizyme inhibitor 1 (AZIN1), Ras homologue family member Q (RHOQ), and
protein tyrosine phosphatase non-receptor type 6 (PTPN6) are found hyper-edited in
cancer compared to healthy tissues, while gamma-aminobutyric acid type A receptor
alpha 3 subunit (Gabra3), glutamate receptor subunit B Glur-B (also known as GRIA2),
and insulin-like growth factor-binding protein 7 (IGFBP7) are found to be hypo-edited
in cancer compared to normal tissue. These editing events have been reported to impact
protein functions. Other recoding editing, such as filamin B (FLNB), cyclin I (CCNI),
coatomer protein complex subunit α (COPA), and the component of oligomeric Golgi
complex 3 (COG3) have not been functionally characterized. Non-coding editomes in
cancer can also be different when compared to the corresponding healthy tissues, such as
with hypo-editing for melanoma and glioma or hyper-editing (of microRNA) in non-small
cell lung carcinoma (NSCLC). This editome is involved in cancer development, progression,
invasion, metastatic potential, recurrence, and resistance (reviewed by [18]).
ADARs are also associated with immunity in several ways. First, the elongated form
of ADAR1 is located in the cytosol and is induced by type I interferon, while constitutive
ADAR2 and the short form of ADAR1 are nuclear. Second, by editing dsRNA, ADARs
avoid the stimulation of innate immune responses by endogenous dsRNA [23] and thereby,
lowering ADAR1 increases tumor inflammation [24,25]. Third, adaptive immunity is im-
pacted by ADARs; a recent report shows that peptides containing amino acids generated
through ADAR-recoding events are human leukocyte antigen (HLA) ligands. In particu-
lar, CCNI-edited peptides act as cancer antigens capable of activating tumor infiltrating
lymphocytes (TILs) and thereby mediate cancer cell death in melanoma [26]. Thus, ADAR-
recoding can impact the Major Histocompatibility Complex (MHC) ligandome and thereby
the specific anti-cancer T-cell response.
Although ADARs affect immunity, studies investigating the potential relationship
between editome and cancer immune evasion are lacking. Melanoma is the most aggressive
form of skin cancer and is currently best treated through the administration of immune
checkpoint inhibitors: monoclonal antibodies blocking negative signals generated by
cytotoxic T-lymphocyte-associated protein 4 (Ipilimumab) or programmed cell death-1 (e.g.,
Pembrolizumab or Nivolumab) in activated T lymphocytes [27]. Since such therapies rely
on the potential for the immune system to fight cancer cells, and since ADARs are involved
in the immune response in multiple ways (see above), we used RNA-Seq datasets to analyze
the editome of melanoma cell lines made from tumors obtained before immunotherapy
and from Ipilimumab and Pembrolizumab-resistant (relapsing) metastasis.
2. Materials and Methods
2.1. Patients and Cell Lines
The study was approved by the Kantonale Ethikkommission under approval number
KEK-ZH Nr. 2014-0425, EK647 and EK800. After informed consent was given by the
patients, biopsies were used to generate melanoma cell lines as described [28]. DNA
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was used to prepare a customized target library using the Nimblegen SeqCap EZ kit
(Nimblegen). Sequencing was performed on an Illumina Hiseq 4000 machine at the
Functional Genomics Center of the University of Zürich (FGCZ). For targeted sequencing,
we sequenced 0.125 lanes per sample, paired-end, with 150 bp reads [28].
Cell line purity was estimated based on the mutant allele frequency (MAF) calculated
as follows: MAF = mutant copies/(wild-type copies + mutant copies). Mutations in BRAF
(V600E) and NRAS (Q61R, Q61K, Q61L) in melanoma are reported to be heterozygous,
and thus cell line purity was calculated as 2 × MAF. RNA was extracted with the QIAGEN
RNeasy kit. RNA capture was performed with the TruSeq RNA library Prep Kit v2
(Illumina). RNA sequencing was sequenced at 125 bp paired end on a HiSeq4000 at
the FGCZ.
Datasets for 14 patients were available for analysis. The samples were grouped by
treatment: 12 samples were assigned to the group not yet subjected to Ipilimumab and
Pembrolizumab therapy (12 cell lines taken from 10 patients) and 11 samples were assigned
to the relapsed group (11 cell lines taken from 4 relapsing patients during treatment by
Ipilimumab and Pembrolizumab). Those relapses happened during immunotherapy as
they appeared within less than one month after the last antibody injection. For two patients,
we collected cell lines before immunotherapy and at the point of relapse.
Raw sequencing reads and RNA counts can be retrieved with GEO accession number
GSE162095 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162095).
2.2. Bioinformatics and Statistics
Gene-level counts were quantified from pair-end reads aligned to the GRCh38 genome
using the quantMode option implemented in STAR (it enables the aligner to count number
reads per gene while mapping) [29]. A differential gene expression analysis was performed
using Qlucore software v 3.5. and using the R script for limma-voom [30]. Significant
differential expression was set to p < 0.05 and the false discovery rate q < 0.05. Gene
expression levels for the ADAR genes were obtained from our USZ melanoma website
http://phil.shinyapps.io/ZMCE. Differences between the two groups of patient samples
were analyzed through an unpaired t-test conducted in GraphPad where p < 0.05 values
were considered significant. RNA editing events were quantified with ExpEdit [31–34], a
web interface based on REDItools [31]. The program explores known human RNA editing
positions annotated in DARNED (approximately 333,215 edited sites, of which 221,595 are
A-to-G edited sites) from FASTQ RNA-seq input files. The default settings displayed by the
interface were selected for analysis: the qPhred score was set to ≥10 (base quality score),
and the mapping quality score was set to ≥20 [26]. The obtained files were adapted for
further analysis with Qlucore software v 3.5 focusing on editing events of ≥10%. Recoding
and non-recoding editing was analyzed separately with the exclusion of known Single
Nucleotide Polymorphism (SNPs) from dbSNP and of any nucleotide changes that did not
resemble A to I (G) [9]. Principal component analysis (PCA) plots and heat maps applying
hierarchical clustering were generated using Qlucore software. The Alu editing events
were analyzed with an unpaired t-test with the Benjamini and Hochberg false discovery
rate multiple testing correction where significantly different Alu editing was measured
with a p value of <0.05 and a q value of <0.1. Alu editing indexes were calculated as the
ratio of the sum of the reads with edited sites (I = G in DARNED) to the total number of
reads [22]. Correlation plots were analyzed in GraphPad applying Pearson correlation,
where a p value of <0.05 was considered significant.
3. Results
We analyzed 23 RNA seq; 12 datasets were collected from cell lines made from biopsies
before the administration of immune checkpoint inhibitors (“before IT”), and 11 datasets
were collected from cell lines made from biopsies of relapsing melanoma in patients
treated with Ipilimumab and Pembrolizumab (“relapsed”) (Table 1). Clinical features of
the melanoma patients from which cell lines were derived are indicated for each patient in
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Table 1 and for both groups in Table 2. Our methods to establish cell lines were optimized
so that melanoma cells were more effectively retrieved and that the cell culture represented
the full range of in vivo tumor heterogeneity [28]. It is not possible to verify that the cell
lines will have similar gene expressions or editing profiles than tumor cells in the biopsies,
however as all cell lines analyzed here were produced in the exact same conditions, we
would expect that if the cell culture derivation would affect gene expression or editing, it
would be similar for all, thus not affecting the comparison between the two groups. From
a multivariant analysis of limma and voom, no gene was found to be significantly up- or
downregulated in one group or the other when p values of less than 0.05 and q values of less
than 0.05 were used (Supplementary Figure S1A and Supplementary Table S1). In addition,
no clear clustering of the two groups can be evidenced using PCA (Supplementary Figure
S1B). Thus, we extended our transcriptome analysis by exploring the role of ADARs in
checkpoint inhibitor immunotherapies against melanoma (Supplementary Table S2).
Table 1. Patients and corresponding cell lines. The table presents the patients’ demographics and treatments as well as the




Cell Lines Treatment Immunotherapy Duration
Cell Line
Purity
Patient 1 M Metastasis Lymph node MM130820 Before IT 87%
Patient 2
F Metastasis Trunk MM150325 Before IT 98%
F Metastasis Trunk MM150604 Relapsed Ipilimumab 3 weeks 74%
Patient 3 F Primary Lymph node MM140905 Before IT 99%
Patient 4
M Metastasis Back M130107 Before IT 59%
M Metastasis Lymph node M121102 Before IT 65%
Patient 5 F Metastasis Lung M121008 Before IT 20%
Patient 6 F Metastasis Lymph node MM130626 Before IT 60%
Patient 7
F Metastasis Leg MM130106 Before IT 57%
F Metastasis Leg MM131205 Relapsed Ipilimumab 3 weeks 78%
F Metastasis Leg MM131206 Relapsed Ipilimumab 3 weeks 65%
Patient 8
M Metastasis Trunk MM150405 Before IT 58%
M Metastasis Lymph node M150404 Before IT
Patient 9 F Metastasis Skin MM130926 Before IT 50%
Patient 10 F Metastasis Skin M980513 Before IT 83%
Patient 11
M Metastasis Arm MM140902 Relapsed Ipilimumab 3 months 100%
M Metastasis Arm M130830 Relapsed Ipilimumab 3 months 100%
Patient 12 M Metastasis Back MM130434 Relapsed Ipilimumab 3 months 77%
Patient 13 M Metastasis Trunk MM121224 Relapsed Ipilimumab 3 months 75%
Patient 14
M Metastasis Skin M130420 Relapsed Ipilimumab 10 days 100%
M Metastasis Liver M130421 Relapsed Ipilimumab 10 days 100%
M Metastasis Testis M130425 Relapsed Ipilimumab 10 days 100%
M Metastasis Lung MM130427 Relapsed Ipilimumab 10 days 97%
3.1. Expression of the ADAR Genes before IT Versus in Relapsing Tumours
We evaluated changes in gene expression between the two groups for the Adar1 and
Adarb1 genes corresponding to the ADAR1 and ADAR2 enzymes, respectively. The analysis
shows that ADAR1 gene expression (long and short forms of ADAR1 combined) remained
unchanged between the groups (Figure 1A), while ADAR2 was significantly enhanced in
the “relapsed” group (Figure 1B) based on an unpaired t-test. This result was unexpected,
as ADAR2 was previously reported to act as a tumor suppressor [35,36] while ADAR1 has
been preferably deemed a tumor oncogene (reviewed by [18]). Thus, the role of ADARs in
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relapse during therapy by immune checkpoint inhibitors may not be the same as the role
of such enzymes in the natural course of melanoma development.
Table 2. Demographics and characteristics of the cell lines for both groups.
Characteristic
Relapsed
N = 11 1
Before IT
N = 12 1
Age at sampling date 48 (18–60) 61 (32–86)
Sex
F 3 (27%) 7 (58%)
M 8 (73%) 5 (42%)
Mutation
BRAF 2 (18%) 7 (58%)
BRAF and NRAS 1 (9.1%) 0 (0%)
NRAS 8 (73%) 5 (42%)
Excision place
Arm 2 (18%) 0 (0%)
Back 1 (9.1%) 1 (8.3%)
Leg 2 (18%) 1 (8.3%)
Liver 1 (9.1%) 0 (0%)
Lung 1 (9.1%) 1 (8.3%)
Lymph node 0 (0%) 5 (42%)
Skin 1 (9.1%) 2 (17%)
Testis 1 (9.1%) 0 (0%)
Trunk 2 (18%) 2 (17%)
1 Statistics presented: median (minimum-maximum); n (%).
p=0.027n.s.
BA
Figure 1. Adenosine deaminase acting on RNA (ADAR) gene expression. The graphs show for each cell line the gene
expression of ADAR1 (in A) and ADAR2 (in B) in the two groups: before immunotherapy (“Before IT”) and in relapse during
immunotherapy (“Relapsed”). The p value calculated from the unpaired t-test is indicated (“n.s.” stands for non-significant).
3.2. Recoding Editing
Clinically relevant recoding editing in cancer has been reported. Corresponding levels
of editing are shown in Supplementary Figure S2 and Supplementary Table S3. ADAR2 is
responsible for most recoding editing events including COG3_I635V and COPA_I164V [37].
While ADAR2 is upregulated in “relapsed”, the two forms of recoding editing were
not significantly different between “before IT” and “relapsed” (Figure 2A). These forms
of recoding editing show a strong positive correlation with the expression of ADAR2,
confirming their ADAR2 dependence (Figure 2B). The recoding editing of COG3 and
COPA was first identified as clinically relevant in more than one form of cancer in Han
et al. [21]. The editing of COG3 and COPA has been shown to correlate with shortened
progression-free survival in renal clear cell carcinoma, and high levels of COG3 editing
have been associated with resistance to fluorouracil and austocystin D while high levels
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of COPA editing have been significantly associated with resistance to austocystin D and
lapatinib [37]. Meanwhile, it has been reported that RNA editing at both CCNI R75G and
COPA I164V generates MHC-associated epitopes [26]. Our data suggest that in patients
treated with immune checkpoint inhibitors, MHC epitopes derived from edited COPA are
not strongly immunogenic, as otherwise they would be downregulated when the immune










Figure 2. Frequency of recoding editing in component of oligomeric Golgi complex 3 (COG3) and coatomer protein
complex subunit α (COPA). The graphs shown in (A) report the percentage of recoding editing observed in COG3 (position
46090371) and COPA (position 160302244) for the two groups: before immunotherapy (“Before IT”) and relapse during
immunotherapy (“Relapsed”). The correlation plots given in (B) depict the level of ADAR2 expression relative to the editing
frequencies of COG3 and COPA. Correlation coefficient “r” and Pearson correlation value “p” value are indicated. Each dot
shown in the figures corresponds to one cell line. n.s.—not significant.
3.3. Non-Recoding Editing in Alu Elements
The global noncoding editome represented by the Alu editing indexes shows no
differences between the two groups (Figure 3A and Supplementary Table S4). Additionally,
in line with previous reports, we find a positive correlation between ADAR1 expression and
Alu editing indexes (Figure 3B), confirming ADAR1’s major contribution to the noncoding
editome. However, a focus on non-recoding single editing sites based on a qPhred score
of ≥10 indicates Alu hyper-editing in relapsed samples of Gap junction gamma-1 protein
(GJC1) at site 42877641 (Figure 3C and Supplementary Tables S5 and S6). Interestingly,
GJC1 Alu editing frequency at this site shows no correlation with ADAR1 expression, but
it correlates positively with ADAR2 expression (Figure 3D). This editing of Alu elements
has been observed for nuclear-retained Cat2 transcribed nuclear RNA [38]. Furthermore,
Alu editing in GJC1 is reported as clinically relevant, showing differential editing levels
across tumor subtypes and tumor stages and correlating with patients’ overall survival
rates [21]. However, further studies must be conducted to determine the contributions of
this Alu editing to cancer progression and to responses to therapy.











































Figure 3. Non-coding editing in Alu elements. Alu editing indexes were calculated for each cell line collected from tumors
before immunotherapy (“Before IT”) or from tumors relapsing during immunotherapy (“Relapsed”). The graph shown
in (A) represents the Alu editing index for each cell line of each group (non-significant p value according to an unpaired
t-test). The correlation plots given in (B) report the Alu editing indexes according to ADAR1 or ADAR2 expression. The
heatmap given in (C) indicates the level of Alu editing observed in genes with a qPhred score of ≥10. The graphs shown in
(D) report the Alu editing frequency observed in Gap junction gamma-1 protein (GJC1) compared to the level of ADAR1
and ADAR2 expression. In the correlation plots, correlation coefficient “r” and Pearson correlation value “p” are shown.
Each dot in the graphs or plots corresponds to one cell line. n.s.—not significant.
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3.4. Principal Component Analysis
To obtain an overview of potential differences in editing patterns observed between
“Before IT” tumors and “Relapsed” during treatment with checkpoint inhibitors, we applied
a principal component analysis. It was done using the two group comparison statistical
analysis (t-test) provided by the Qlucore software and the following parameters: filtering
by variance 0.15, p value was 0.05, and q value was 0.775. The outcome by the software
was 57 Alu editing sites in 57 genes for the sample representation in a 3D PCA plot and
heatmap representation of Alu editing sites (Figure 4 and Supplementary Table S7). Editing
events were not normalized as a single editing site was used as a unique identifier for
variable analysis and not the complete gene with all the editing events. From the PCA plot
including the 57 Alu editing events, we can clearly separate the two groups of patients
based on the corresponding cell lines. This separation is confirmed in a hierarchically
clustered heatmap showing that Alu signatures can differentiate cell lines from patients
who relapse from cell lines taken from patients before IT (Figure 4A,B). Conversely, no




Figure 4. Treatment-based distribution for Alu editing events. A 3D principal component analysis (PCA) plot representation
of samples is presented in (A). Cell lines are made from tumors before immunotherapy (“Before IT”) or from tumors
relapsing during immunotherapy (“Relapsed”). A clear separation of samples based on 57 different Alu editing sites is
shown. For the 57 Alu editing sites hierarchically clustered, a heatmap representation is given in (B). The scale on the right
denotes the editing frequency.
Collectively, our study reveals an editing signature in Alu elements that characterizes
tumors relapsing during treatment with immune checkpoint inhibitors (Figures 3C and 4).
Surprisingly, this special signature may be associated with the higher expression of ADAR2
(at least for GJC1, Figure 3D). While ADAR2 has been envisioned as a tumor suppressor,
its increased expression in “relapses” would indicate that under treatment with immune
checkpoint inhibitors, inhibiting ADAR2 could help prevent tumor recurrence. Some
targets of ADAR2, mostly recoding editing events may be of relevance, but they could not
be identified in the present study (non-significant changes in the recoding editing of COPA
and COG3 and no grouping of recoding events, Supplementary Figure S2). Meanwhile, the
known recoding editing that generates MHC epitopes that are recognized by anti-cancer
T-cells was not downregulated, indicating the weak significance of these epitopes for the
immune control of cancer. The combination of several recoding and non-coding editing
events (Alu editing of GJC1) eventually mediated by ADAR2 may be responsible for the
potential advantages that the overexpression of this gene provides for recurrence during
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treatment with immune checkpoint inhibitors. Although RNAseq data from whole tumor
tissues are publicly available (for example from Liu et al. [39]), an analysis of A to G editing
and its eventual correlation with clinical outcome would require the generation of tumor
cell lines. Indeed, in whole tumor tissues, RNA sequences are originating not solely from
tumor cells but also from non-tumor stroma cells, immune cells, etc. Thus, editing analysis
of these sequencing files would not provide information exclusively on melanoma cells but
would primarily reflect the heterogeneity of the tumor samples (percentages of immune
cells, non-tumor cells, blood vessels, etc.) that varies from one sample to another. We
foresee that our results will galvanize the analysis of A to G editing in tumor cell lines
made from patients with a precisely known cancer history and will enable the identification
of further correlations between editing and cancer outcome. Our study does not address
the biological or biochemical phenomenon that connects the Alu-editing signature to the
immunotherapeutic treatment. It however is the very first study that shows a correlation
between RNA editing in melanoma and clinical outcome. We foresee that based on those
observational results, further studies can be undertaken to more precisely decipher the
mechanisms leading to the differential RNA editing in tumor cells during immunotherapy
of cancer.
4. Conclusions
Our study points to differential editing in Alu sequences between melanoma cell lines
obtained before therapy and melanoma cell lines made from relapses during treatment
with immune checkpoint inhibitors. Those findings may be of relevance for diagnostic and
prognostic tools as well as for the development of drugs or treatments that may lower the
risks of relapses during therapy with immune checkpoint inhibitors.
Supplementary Materials: The following are available online at https://www.mdpi.com/2311-5
53X/7/1/5/s1, Figure S1: Analysis of gene expression, Figure S2: Heat map representation of all
recoding editing events, Table S1: Top 50 differentially expressed genes, Table S2: List and frequency
of all editing events, Table S3: Recoding editing, Table S4: Alu editing indexes, Table S5: Top 10
differentially edited Alu, Table S6: Alu editing datasheet, Table S7: Alu editing events included in the
PCA.
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Abbreviations
ADAR adenosine deaminase acting on RNA
ADAT adenosine deaminase acting on tRNA
Alu Arthrobacter luteus
AZIN1 encoding antizyme inhibitor 1
CCNI cyclin I
COG3 component of oligomeric Golgi complex 3
COPA coatomer protein complex subunit α
FLNB filamin B
Gabra3 gamma-aminobutyric acid type A receptor alpha 3 subunit
GJC1 Gap junction gamma-1 protein
Glur-B glutamate receptor subunit B
HLA human leukocyte antigen
IGFBP7 insulin-like growth factor-binding protein 7
LINE Long interspersed element
NEIL1 DNA base excision repair glycosylase enzyme NEI-like protein 1
NSCLC non-small cell lung carcinoma
PTPN6 protein tyrosine phosphatase non-receptor type 6
RHOQ Ras homologue family member Q
Tils tumor infiltrating lymphocytes
References
1. Hsiao, Y.E.; Bahn, J.H.; Yang, Y.; Lin, X.; Tran, S.; Yang, E.W.; Quinones-Valdez, G.; Xiao, X. RNA editing in nascent RNA affects
pre-mRNA splicing. Genome Res. 2018, 28, 812–823. [CrossRef] [PubMed]
2. Bass, B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 2002, 71, 817–846. [CrossRef] [PubMed]
3. Levanon, E.Y.; Hallegger, M.; Kinar, Y.; Shemesh, R.; Djinovic-Carugo, K.; Rechavi, G.; Jantsch, M.F.; Eisenberg, E. Evolutionarily
conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res. 2005, 33, 1162–1168. [CrossRef] [PubMed]
4. Gerber, A.P.; Keller, W. RNA editing by base deamination: More enzymes, more targets, new mysteries. Trends Biochem. Sci. 2001,
26, 376–384. [CrossRef]
5. Blanc, V.; Davidson, N.O. C-to-U RNA editing: Mechanisms leading to genetic diversity. J. Biol. Chem. 2003, 278, 1395–1398.
[CrossRef]
6. Picardi, E.; Manzari, C.; Mastropasqua, F.; Aiello, I.; D’Erchia, A.M.; Pesole, G. Profiling RNA editing in human tissues: Towards
the inosinome Atlas. Sci. Rep. 2015, 5, 14941. [CrossRef]
7. Nishikura, K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat. Rev. Mol. Cell Biol. 2016, 17, 83–96. [CrossRef]
8. Athanasiadis, A.; Rich, A.; Maas, S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. Plos
Biol. 2004, 2, e391. [CrossRef]
9. Bazak, L.; Haviv, A.; Barak, M.; Jacob-Hirsch, J.; Deng, P.; Zhang, R.; Isaacs, F.J.; Rechavi, G.; Li, J.B.; Eisenberg, E.; et al. A-to-I
RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 2014, 24, 365–376.
[CrossRef]
10. Kim, D.D.; Kim, T.T.; Walsh, T.; Kobayashi, Y.; Matise, T.C.; Buyske, S.; Gabriel, A. Widespread RNA editing of embedded alu
elements in the human transcriptome. Genome Res. 2004, 14, 1719–1725. [CrossRef]
11. Nishikura, K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem. 2010, 79, 321–349. [CrossRef]
[PubMed]
12. Hood, J.L.; Emeson, R.B. Editing of neurotransmitter receptor and ion channel RNAs in the nervous system. Curr. Top. Microbiol.
Immunol. 2012, 353, 61–90. [PubMed]
13. Levanon, E.Y.; Eisenberg, E.; Yelin, R.; Nemzer, S.; Hallegger, M.; Shemesh, R.; Fligelman, Z.Y.; Shoshan, A.; Pollock, S.R.;
Sztybel, D.; et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol. 2004,
22, 1001–1005. [CrossRef] [PubMed]
14. Wang, Q.; Khillan, J.; Gadue, P.; Nishikura, K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic
erythropoiesis. Science 2000, 290, 1765–1768. [CrossRef] [PubMed]
15. Higuchi, M.; Maas, S.; Single, F.N.; Hartner, J.; Rozov, A.; Burnashev, N.; Feldmeyer, D.; Sprengel, R.; Seeburg, P.H. Point
mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR. Nature 2000, 406, 78–81.
[CrossRef] [PubMed]
Non-coding RNA 2021, 7, 5 11 of 11
16. Wahlstedt, H.; Daniel, C.; Enstero, M.; Ohman, M. Large-scale mRNA sequencing determines global regulation of RNA editing
during brain development. Genome Res. 2009, 19, 978–986. [CrossRef]
17. Roth, S.H.; Danan-Gotthold, M.; Ben-Izhak, M.; Rechavi, G.; Cohen, C.J.; Louzoun, Y.; Levanon, E.Y. Increased RNA Editing May
Provide a Source for Autoantigens in Systemic Lupus Erythematosus. Cell Rep. 2018, 23, 50–57. [CrossRef]
18. Tusup, M.; Kundig, T.; Pascolo, S. Epitranscriptomics of cancer. World J. Clin. Oncol. 2018, 9, 42–55. [CrossRef]
19. Maas, S.; Kawahara, Y.; Tamburro, K.M.; Nishikura, K. A-to-I RNA editing and human disease. RNA Biol. 2006, 3, 1–9. [CrossRef]
20. Keegan, L.P.; Gallo, A.; O’Connell, M.A. The many roles of an RNA editor. Nat. Rev. Genet. 2001, 2, 869–878. [CrossRef]
21. Han, L.; Diao, L.; Yu, S.; Xu, X.; Li, J.; Zhang, R.; Yang, Y.; Werner, H.M.J.; Eterovic, A.K.; Yuan, Y.; et al. The Genomic Landscape
and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell 2015, 28, 515–528. [CrossRef] [PubMed]
22. Paz-Yaacov, N.; Bazak, L.; Buchumenski, I.; Porath, H.T.; Danan-Gotthold, M.; Knisbacher, B.A.; Eisenberg, E.; Levanon, E.Y.
Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors. Cell Rep. 2015, 13, 267–276.
[CrossRef] [PubMed]
23. Mannion, N.M.; Greenwood, S.M.; Young, R.; Cox, S.; Brindle, J.; Read, D.; Nellåker, C.; Vesely, C.; Ponting, C.P.; McLaughlin,
P.J.; et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 2014, 9, 1482–1494. [CrossRef]
[PubMed]
24. Ishizuka, J.J.; Manguso, R.T.; Cheruiyot, C.K.; Bi, K.; Panda, A.; Iracheta-Vellve, A.; Miller, B.C.; Du, P.P.; Yates, K.B.; Dubrot, J.;
et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nat. Cell Biol. 2019, 565, 43–48. [CrossRef]
[PubMed]
25. Liu, H.; Golji, J.; Brodeur, L.K.; Chung, F.S.; Chen, J.T.; Debeaumont, R.S.; Bullock, C.P.; Jones, M.D.; Kerr, G.; Li, L.; et al.
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat. Med. 2019, 25, 95–102. [CrossRef]
26. Zhang, M.; Fritsche, J.; Roszik, J.; Williams, L.J.; Peng, X.; Chiu, Y.; Tsou, C.-C.; Hoffgaard, F.; Goldfinger, V.; Schoor, O.; et al. RNA
editing derived epitopes function as cancer antigens to elicit immune responses. Nat. Commun. 2018, 9, 1–10. [CrossRef]
27. Ribas, A.; Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science 2018, 359, 1350–1355. [CrossRef]
28. Raaijmakers, M.I.G.; Widmer, D.S.; Maudrich, M.; Koch, T.; Langer, A.; Flace, A.; Schnyder, C.; Dummer, R.; Levesque, M.P. A
new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Exp. Dermatol. 2015,
24, 377–380. [CrossRef]
29. Dobin, A.; Davis, C.A.; Schlesinger, F.; Drenkow, J.; Zaleski, C.; Jha, S.; Batut, P.; Chaisson, M.; Gingeras, T.R. STAR: Ultrafast
universal RNA-seq aligner. Bioinformatics 2013, 29, 15–21. [CrossRef]
30. Law, C.W.; Chen, Y.; Shi, W.; Smyth, G.K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts.
Genome Biol. 2014, 15, R29. [CrossRef]
31. Picardi, E.; Pesole, G. REDItools: High-throughput RNA editing detection made easy. Bioinformatics 2013, 29, 1813–1814.
[CrossRef] [PubMed]
32. D’Antonio, M.; Picardi, E.; Castrignanò, T.; D’Erchia, A.M.; Pesole, G. Exploring the RNA Editing Potential of RNA-Seq Data by
ExpEdit. Adv. Struct. Saf. Stud. 2014, 1269, 327–338.
33. Picardi, E.; D’Antonio, M.; Carrabino, D.; Castrignanò, T.; Pesole, G. ExpEdit: A webserver to explore human RNA editing in
RNA-Seq experiments. Bioinformatics 2011, 27, 1311–1312. [CrossRef] [PubMed]
34. Zaranek, A.W.; Levanon, E.Y.; Zecharia, T.; Clegg, T.; Church, G.M. A Survey of Genomic Traces Reveals a Common Sequencing
Error, RNA Editing, and DNA Editing. PLoS Genet. 2010, 6, e1000954. [CrossRef] [PubMed]
35. Shelton, P.M.; Duran, A.; Nakanishi, Y.; Reina-Campos, M.; Kasashima, H.; Llado, V.; Ma, L.; Campos, A.; Garcia-Olmo, D.;
Garcia-Arranz, M.; et al. The Secretion of miR-200s by a PKCzeta/ADAR2 Signaling Axis Promotes Liver Metastasis in Colorectal
Cancer. Cell Rep. 2018, 23, 1178–1191. [CrossRef]
36. Galeano, F.; Rossetti, C.; Tomaselli, S.; Cifaldi, L.; Lezzerini, M.; Pezzullo, M.; Boldrini, R.; Massimi, L.; Di Rocco, C.M.; Locatelli,
F.; et al. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis.
Oncogene 2013, 32, 998–1009. [CrossRef]
37. Peng, X.; Xu, X.; Wang, Y.; Hawke, D.; Yu, S.; Han, L.; Zhou, Z.; Mojumdar, K.; Jeong, K.J.; Labrie, M.; et al. A-to-I RNA Editing
Contributes to Proteomic Diversity in Cancer. Cancer Cell 2018, 33, 817–828.e7. [CrossRef]
38. Anantharaman, A.; Tripathi, V.; Khan, A.; Yoon, J.-H.; Singh, D.K.; Gholamalamdari, O.; Guang, S.; Ohlson, J.; Wahlstedt, H.;
Öhman, M.; et al. ADAR2 regulates RNA stability by modifying access of decay-promoting RNA-binding proteins. Nucleic Acids
Res. 2017, 45, 4189–4201. [CrossRef]
39. Liu, D.; Schilling, B.; Liu, D.; Sucker, A.; Livingstone, E.; Jerby-Arnon, L.; Zimmer, L.; Gutzmer, R.; Satzger, I.; Loquai, C.; et al.
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat.
Med. 2019, 25, 1916–1927. [CrossRef]
